RAD52 and breast carcinoma: In a recent study, a truncating variant of RAD52 has been found to significantly reduce the breast cancer risk in BRCA2 mutation carriers, which supports a role for RAD52 as a genetic modifier of cancer predisposition associated with BRCA2 loss (Adamson et al., 2020).